Atossa Therapeutics, Inc. ATOS
Set alert
2.17 USD -0.06 -2.69%
At close · Oct 30
2.28 +0.11 +5.04%
After hours · Oct 30, 5:25 PM ET
2.15 Day range 2.43
1.75 52-week range 13.50
- YTD
- -75.48%
- 1 year
- -83.56%
- Open
- 2.25
- Prev close
- 2.23
- Mkt cap
- 21.66M
- Vol
- 32.90K
- Avg vol
- 71.57K
- EPS
- -4.45
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 2.15
- High
- 2.43
- Forward P/E
- -3.81
- Beta
- 1.23
- Short ratio
- 14.73
- Inst. own
- 28.16%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.31
- 200-d avg
- 1.39
- 1y target
- 6.00
2Y chart
Events in this range
- Oct 31, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Nov 5, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Nov 12, 2024Earnings: -0.05; estimate -0.06; surprise 16.67%
- Nov 13, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Dec 9, 2024Rating: Ascendiant Capital · Buy → Buy
- Dec 12, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Dec 13, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Feb 2, 2026Split: 1 for 15
Signals (81)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Oct 27, 2026 | 4 days ago |
| SMA: Bullish | Oct 13, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 12, 2026 | 2 weeks ago |
| SMA: Bullish | Oct 5, 2026 | 3 weeks ago |
| MACD: Buy Signal | Oct 2, 2026 | 4 weeks ago |
| RSI: Oversold | Sep 25, 2026 | 1 month ago |
| SMA: Bearish | Sep 15, 2026 | 1 month ago |
| SMA: Bullish | Sep 11, 2026 | 1 month ago |
| SMA: Bearish | Sep 9, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 1, 2026 | 2 months ago |
| SMA: Bullish | Aug 13, 2026 | 2 months ago |
| MACD: Buy Signal | Jul 1, 2026 | 4 months ago |
| RSI: Oversold | Jun 11, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 3, 2026 | 5 months ago |
| MACD: Buy Signal | May 29, 2026 | 5 months ago |
| SMA: Bearish | May 12, 2026 | 5 months ago |
| MACD: Sell Signal | Apr 29, 2026 | 6 months ago |
| SMA: Bullish | Apr 13, 2026 | 6 months ago |
| MACD: Buy Signal | Feb 24, 2026 | 8 months ago |
| MACD: Sell Signal | Feb 2, 2026 | 9 months ago |
| RSI: Oversold | Feb 2, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 16, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 15, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 8, 2026 | 9 months ago |
| MACD: Sell Signal | Dec 17, 2025 | 10 months ago |
| SMA: Bearish | Dec 15, 2025 | 10 months ago |
| SMA: Bearish | Dec 12, 2025 | 10 months ago |
| SMA: Bullish | Dec 11, 2025 | 10 months ago |
| SMA: Bullish | Dec 10, 2025 | 10 months ago |
| MACD: Buy Signal | Dec 4, 2025 | 11 months ago |
| MACD: Sell Signal | Dec 2, 2025 | 11 months ago |
| RSI: Oversold | Dec 2, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 28, 2025 | 11 months ago |
| RSI: Oversold | Nov 19, 2025 | 11 months ago |
| SMA: Bearish | Nov 12, 2025 | 11 months ago |
| SMA: Bullish | Nov 10, 2025 | 11 months ago |
| SMA: Bearish | Nov 6, 2025 | 11 months ago |
| SMA: Bearish | Oct 29, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 17, 2025 | 1 year ago |
| RSI: Overbought | Oct 3, 2025 | 1 year ago |
| SMA: Bullish | Sep 26, 2025 | 1 year ago |
| SMA: Bearish | Sep 22, 2025 | 1 year ago |
| SMA: Bullish | Sep 18, 2025 | 1 year ago |
| SMA: Bullish | Sep 11, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 26, 2025 | 1 year ago |
| SMA: Bearish | Jul 31, 2025 | 1 year ago |
| SMA: Bullish | Jul 29, 2025 | 1 year ago |
| SMA: Bearish | Jul 24, 2025 | 1 year ago |
| SMA: Bullish | Jul 23, 2025 | 1 year ago |
| SMA: Bearish | Jul 18, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 18, 2025 | 1 year ago |
| SMA: Bullish | Jul 9, 2025 | 1 year ago |
| SMA: Bearish | Jul 7, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 7, 2025 | 1 year ago |
| SMA: Bullish | Jul 3, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 1, 2025 | 1 year ago |
| SMA: Bearish | Jun 30, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 27, 2025 | 1 year ago |
| SMA: Bullish | Jun 24, 2025 | 1 year ago |
| SMA: Bearish | Jun 18, 2025 | 1 year ago |
| SMA: Bullish | May 30, 2025 | 1 year ago |
| SMA: Bearish | May 29, 2025 | 1 year ago |
| MACD: Sell Signal | May 22, 2025 | 1 year ago |
| RSI: Overbought | May 14, 2025 | 1 year ago |
| RSI: Overbought | Apr 30, 2025 | 1 year ago |
| SMA: Bullish | Apr 23, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 15, 2025 | 1 year ago |
| MACD: Sell Signal | Apr 1, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 14, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 13, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 6, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 3, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 13, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 12, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 21, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 17, 2025 | 1 year ago |
| RSI: Oversold | Jan 17, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 2, 2025 | 1 year ago |
| MACD: Sell Signal | Dec 31, 2024 | 1 year ago |
| MACD: Buy Signal | Dec 26, 2024 | 1 year ago |
| RSI: Oversold | Dec 18, 2024 | 1 year ago |
Key statistics
- Market cap
- 129.58M
- Enterprise value
- 46.47M
- Trailing P/E
- 0.00
- Forward P/E
- -3.81
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 1.76
- EPS (TTM)
- -0.21
- Beta
- 1.23
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -12.76M
- Total cash
- 74.77M
- Total debt
- 0
- Return on equity
- -31.30%
- Shares outstanding
- 125.80M
- Short % of float
- 9.23%
- 50-day average
- 1.31
- 200-day average
- 1.39
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 6.00 +176.5% upside
Now 2.17
- Target (low)
- 4.00
- Target (mean)
- 6.00
- Target (high)
- 7.00
Ratings (0m) 4 4 buy · 0 hold · 0 sell
- Strong buy2
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.06.
Financials — quick view
ATOS Revenue — quarterly 0
ATOS Net income — quarterly -8.49M
ATOS EPS — quarterly -0.95
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.06 | -0.05 | +0.01 | +16.67% |
| Aug 12, 2024 | Jun 1, 2024 | -0.05 | -0.05 | 0.00 | 0.00% |
| May 13, 2024 | Mar 1, 2024 | -0.07 | -0.05 | +0.02 | +28.57% |
| Apr 1, 2024 | Dec 1, 2023 | -0.05 | -0.06 | -0.01 | -20.00% |
| Nov 13, 2023 | Sep 1, 2023 | 0.00 | -0.05 | — | — |
| Aug 14, 2023 | Jun 1, 2023 | 0.00 | -0.06 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 13, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Dec 12, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Dec 9, 2024 | Ascendiant Capital | main | Buy | Buy |
| Nov 13, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Nov 5, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 31, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Atossa Therapeutics, Inc.
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- atossatherapeutics.com
News
- Atossa Therapeutics Confirms Shares To Begin Trading With One Stapled Contingent Value Right As Of Close Of Business On October 19
- Atossa Therapeutics Common Stock to Begin Trading with Stapled Contingent Value Rights After Close of Business Today
- Atossa Therapeutics Inks Stapled Contingent Value Rights Agreement With VStock Transfer; Atossa Declares Dividend Of One Stapled CVR For Each Share Of Atossa Common Stock
- Atossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation in Potential Priority Review Voucher Value
- Ascendiant Capital Maintains Buy on Atossa Therapeutics, Raises Price Target to $25
- Atossa Therapeutics Announces Plan to Issue Stapled CVR for Shareholders Tied to Potential Rare Pediatric Disease Priority Review Voucher
- Atossa Therapeutics CEO Dr. Steven Quay to Participate in ARDD 2026 Panel on Clinical Trials and Regulatory Pathways for Diseases of Aging
- Atossa Therapeutics Q2 EPS $(0.95) Beats $(1.02) Estimate
- Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
- Atossa Therapeutics Announces npj Breast Cancer Publication Highlighting Novel Endoxifen-Based Compounds In ESR1-Mutant Breast Cancer Models
Your note
Sign in to keep a note on ATOS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| FINN JONATHAN F. | Director | Purchase | Apr 9, 2024 | 25,000 |
| WEAVER GREGORY L | Officer and Director | Sale | Nov 14, 2023 | 55 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 7.68% | 9,667,615 | 9.96M | Sep 29, 2024 |
| Vanguard Group Inc | 5.25% | 6,598,296 | 6.80M | Sep 29, 2024 |
| Geode Capital Management, LLC | 2.24% | 2,814,446 | 2.90M | Sep 29, 2024 |
| State Street Corporation | 1.38% | 1,732,221 | 1.78M | Sep 29, 2024 |
| Renaissance Technologies, LLC | 1.04% | 1,310,070 | 1.35M | Sep 29, 2024 |
| Northern Trust Corporation | 0.76% | 954,199 | 982.82K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 3.13% | 3,939,441 | 4.06M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.60% | 3,268,268 | 3.37M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 1.33% | 1,667,748 | 1.72M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 1.04% | 1,304,195 | 1.34M | Aug 30, 2024 |
| iShares Russell 2000 Value ETF | 0.85% | 1,065,227 | 1.10M | Oct 30, 2024 |
| Fidelity Extended Market Index Fund | 0.54% | 676,434 | 696.73K | Oct 30, 2024 |